Overview
Mitigating Veno-occlusive Disease Risk in Patients Treated for Relapsed/Refractory B-cell Precursor ALL
Digital FAQ
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
Veno-occlusive disease (VOD) is a life-threatening condition associated with treatment of relapsed/refractory B-cell precursor acute lymphoblastic leukemia (R/R ALL). Early recognition and management are paramount to recovery. This self-directed education was designed for diverse members of the interdisciplinary care team that treat or may encounter patients with R/R ALL who are at risk for VOD. Expert commentary from Partow Kebriaei, MD provides answers to common questions faced by clinicians when diagnosing and managing VOD.
This activity is intended for hematologists/oncologists, gastroenterologists, hospitalists, emergency medicine, and the multidisciplinary team involved in care of patients with ALL.
New, highly effective therapies with different mechanisms of action are available for R/R ALL in addition to HSCT. To help choose among the varying array of therapeutic options, clinicians need to know the various characteristics and potential adverse effects of these agents. This includes prevention, identification, and treatment of VOD, a serious potential adverse event. At-risk patients require frequent monitoring to ensure early recognition and treatment. All clinicians on the interdisciplinary R/R ALL team need to receive education on how to better optimize their communication and decision-making to improve the management of their patients.
Upon completion of this activity, participants will be able to:
• Create optimal relapsed/refractory acute lymphoblastic leukemia (R/R ALL) treatment plans in terms of treatment selection, sequencing, and dosing while incorporating patient point-of-care (in-patient versus out-patient)
• Incorporate strategies and tools to mitigate and manage veno-occlusive disease (VOD) risk in patients with R/R ALL proceeding to HSCT
• Outline tactics to facilitate interdisciplinary communication and decision-making
• Create optimal relapsed/refractory acute lymphoblastic leukemia (R/R ALL) treatment plans in terms of treatment selection, sequencing, and dosing while incorporating patient point-of-care (in-patient versus out-patient)
• Incorporate strategies and tools to mitigate and manage veno-occlusive disease (VOD) risk in patients with R/R ALL proceeding to HSCT
• Outline tactics to facilitate interdisciplinary communication and decision-making
Sponsored by The University of Chicago Pritzker School of Medicine and the Academy for Continued Healthcare Learning (ACHL).
Supported by an educational grant from Pfizer.
Partow Kebriaei, MD
Professor, Department of Stem Cell Transplantation
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX
Professor, Department of Stem Cell Transplantation
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX
The University of Chicago Pritzker School of Medicine requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity.
The following financial relationships have been provided:
Partow Kebriaei, MD
Advisory board: Jazz Pharmaceuticals, Kite Pharma, Inc., Novartis, Pfizer Inc., ZIOPHARM Oncology, Inc.
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Prophylaxis with defibrotide or ursodiol
ACHL and the University of Chicago Pritzker School of Medicine staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. The University of Chicago Pritzker School of Medicine and ACHL require the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 30 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
The University of Chicago Pritzker School of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other Healthcare Professional Credit
Other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.
